<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR13">
 <label>13.</label>
 <mixed-citation publication-type="other">Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink H-JJ, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiori. Lancet [Internet]. 2017 Nov [cited 2019 Mar 8];390(10107):2073–82. Available from: 
  <ext-link ext-link-type="uri" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S0140673617323401" xmlns:xlink="http://www.w3.org/1999/xlink">https://linkinghub.elsevier.com/retrieve/pii/S0140673617323401</ext-link>.
 </mixed-citation>
</ref>
